Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Levoleucovorin Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0104

    Levoleucovorin and Leucovorin Agents

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0104 alerts

    Get alerted when Policy CC-0104 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and clinical review, including prior authorization, for injectable levoleucovorin and leucovorin agents for methotrexate rescue or toxicity reduction, folic acid antagonist overdose, anemia, fluorouracil-based chemotherapy, and specified oncology indications.

    Policy Summary
    PayerEmpire Bluecross
    PolicyLevoleucovorin and Leucovorin Agents
    Policy CodePolicy CC-0104
    Change TypeModified — annual review
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionUse the applicable medical-necessity criteria to determine coverage when the drug is subject to clinical review or prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 annual review clarified NCCN 2A indications for Khapzory/levoleucovorin, including types of B-cell lymphomas and neuroendocrine tumors.

    The 2026 annual review clarified NCCN 2A indications for Vykoura/leucovorin, including types of neuroendocrine tumors.

    Step therapy was updated to apply specifically to injectable agents and to include levoleucovorin agents in the criteria body.

    HCPCS J3490 and C9310 were removed for Vykoura effective September 30, 2026.

    HCPCS J0644 was added for Vykoura effective October 1, 2026.

    ICD-10-CM codes C7B.00-C7B.09, C7B.8, E16.1, E16.3, and E16.8 were added for Vykoura, levoleucovorin, and Khapzory.

    ICD-10-CM codes C82.00-C82.09 and C82.10-C82.19 were removed from levoleucovorin and Khapzory coding.

    The policy updated NCCN-based recommendations for pediatric acute lymphoblastic leukemia, pediatric aggressive mature B-cell lymphomas, B-cell lymphomas, T-cell lymphomas, and Waldenström macroglobulinemia.

    The policy updated the nomenclature for biliary tract cancers.

    The policy revised the ICD-10-CM diagnosis code set by removing the all-diagnoses designation and adding specified oncology and related diagnosis codes and code ranges.

    The policy updated the HCPCS description for J0642.

    Fusilev was removed from the policy because it is a discontinued product.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Drug products with separate coverage criteria
    NCCN 2AEvidence category cited for multiple oncology uses
    19Age threshold for an alternative approval pathway
    3Coverage pathways in this document segment
    2Levoleucovorin-agent HCPCS codes listed
    All other indicationsRequests not approved when applicable criteria are not met

    Coverage Criteria

    Initial Therapy: Levoleucovorin Agents

    Requests for levoleucovorin agents may be approved when ANY of the following criteria are met:

    ANY of the following

    • Individual is under 19 years of age.
    • Individual is using as a component of high-dose methotrexate therapy in osteosarcoma.
    • Individual is using as a treatment of impaired methotrexate elimination.
    • Individual is using as a treatment of inadvertent over-dosage of folic acid antagonists.
    • Individual is using in combination chemotherapy with fluorouracil-based regimens to treat colorectal adenocarcinoma.
    • Individual is using in combination with high-dose methotrexate when leucovorin is not available in pediatric acute lymphoblastic leukemia or pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma, diffuse B-cell lymphoma, primary mediastinal large B-cell lymphoma, and pediatric post-transplant lymphoproliferative disorders (NCCN 2A).
    • Individual is using in combination with high-dose methotrexate when leucovorin is not available for the management of symptomatic Bing-Neel syndrome in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (NCCN 2A).
    • Individual is using in combination with chemotherapy for one of the following cancers (NCCN 2A)

      • Acute lymphoblastic leukemia (ALL).
      • Acute myeloid leukemia (AML), including blastic plasmacytoid dendritic cell neoplasm (BPDCN).
      • Anal carcinoma.
      • Ampullary adenocarcinoma.
      • Appendiceal neoplasms and cancers, including appendiceal adenocarcinoma, undifferentiated carcinoma not otherwise specified, goblet cell adenocarcinoma, low-grade appendiceal mucinous neoplasm, and high-grade appendiceal mucinous neoplasm.
      • B-cell lymphoma, including diffuse large B-cell lymphoma, high-grade B-cell lymphomas, post-transplant lymphoproliferative disorders, HIV-related B-cell lymphomas, or Burkitt lymphoma.

    Initial Therapy: Vykoura (Leucovorin Calcium)

    Requests for Vykoura (leucovorin calcium) may be approved when ANY of the following criteria are met:

    ANY of the following

    • Individual is under 19 years of age.
    • Individual is using as a rescue after high-dose methotrexate therapy.
    • Individual is using to reduce the toxicity of one of the following

      • Methotrexate in individuals with impaired methotrexate elimination.
      • Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose.
    • Individual is using in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible.

    High-Dose Methotrexate Combination Therapy

    Coverage may be approved when Vykoura (leucovorin calcium) is used in combination with high-dose methotrexate for ANY of the following cancer diagnoses (NCCN 2A):

    ANY of the following

    • Pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma, diffuse B-cell lymphoma, primary mediastinal large B-cell lymphoma, and pediatric post-transplant lymphoproliferative disorders.
    • Waldenström macroglobulinemia/lymphoplasmacytic lymphoma for the management of symptomatic Bing-Neel syndrome.
    • Pediatric acute lymphoblastic leukemia.
    • Pediatric Langerhans cell histiocytosis.
    • Gestational trophoblastic neoplasia.

    Graft-Versus-Host-Disease Prophylaxis

    Coverage may be approved when ALL of the following are met:

    ALL of the following

    • Individual is using Vykoura (leucovorin calcium) as prophylaxis in combination with methotrexate for graft-versus-host disease.
    • Use is supported by DrugDex evidence rating BIIa.

    Levoleucovorin agents are not approved outside the criteria listed above.

    Vykoura is not approved outside the criteria listed above.

    Requests for Vykoura may not be approved when the criteria above are not met or for all other indications.

    Coding Information

    Levoleucovorin Agents HCPCSHCPCS
    J0641Injection, levoleucovorin, not otherwise specified, 0.5 mg. [levoleucovorin calcium]
    J0642Injection, levoleucovorin 0.5 mg [Khapzory]
    Leucovorin Agents HCPCSHCPCS
    J0644Injection, leucovorin calcium (Avyxa), 1 mg [Vykoura]
    Levoleucovorin Agents ICD-10 DiagnosisICD-10
    B20Human immunodeficiency virus [HIV] disease
    C15.3-C17.9Malignant neoplasm of esophagus, stomach, small intestine
    C18.0-C21.8Malignant neoplasm of colon, rectosigmoid junction, rectum, anus and anal canal
    C22.1Intrahepatic bile duct carcinoma
    C23Malignant neoplasm of gallbladder
    C24.1Malignant neoplasm of ampulla of Vater
    C24.0Malignant neoplasm of extrahepatic bile duct
    C24.8Malignant neoplasm of overlapping sites of biliary tract
    C24.9Malignant neoplasm of biliary tract, unspecified
    C25.0-C25.9Malignant neoplasm of pancreas
    1–10 of 54
    1/6
    Leucovorin Agents ICD-10 DiagnosisICD-10
    B20Human immunodeficiency virus [HIV] disease
    C15.3-C17.9Malignant neoplasm of esophagus, stomach, small intestine
    C18.0-C21.8Malignant neoplasm of colon, rectosigmoid junction, rectum, anus and anal canal
    C22.1Intrahepatic bile duct carcinoma
    C23Malignant neoplasm of gallbladder
    C24.0Malignant neoplasm of extrahepatic bile duct
    C24.1Malignant neoplasm of ampulla of Vater
    C24.8Malignant neoplasm of overlapping sites of biliary tract
    C24.9Malignant neoplasm of biliary tract, unspecified
    C25.0-C25.9Malignant neoplasm of pancreas
    1–10 of 59
    1/6
    ICD-10-CM DiagnosisICD-10
    B20ICD-10-CM diagnosis code
    C15.3-C21.8ICD-10-CM diagnosis code range
    C23ICD-10-CM diagnosis code
    C24.1ICD-10-CM diagnosis code
    C24.8-C25.9ICD-10-CM diagnosis code range
    C37ICD-10-CM diagnosis code
    C40.00-C41.9ICD-10-CM diagnosis code range
    C48.1-C48.8ICD-10-CM diagnosis code range
    C52-C53.9ICD-10-CM diagnosis code range
    C56.1-C56.9ICD-10-CM diagnosis code range
    1–10 of 33
    1/4
    HCPCSHCPCS
    J0641Generic levoleucovorin calcium
    J0642HCPCS code; description updated in coding review
    J3490HCPCS code deleted from the policy
    C9043Injection, levoleucovorin

    Provider Actions and Review Requirements

    Prior Authorization

    Clinical Review Required

    When a drug is reviewed for coverage under the member’s medical benefit plan or is otherwise subject to clinical review, including prior authorization, the listed clinical criteria will be used to determine whether the drug meets applicable medical-necessity requirements for the intended or prescribed purpose.

    Denial Risk

    Levoleucovorin Criteria Not Met

    Requests for levoleucovorin agents, including levoleucovorin calcium and Khapzory, may not be approved when the applicable clinical criteria are not met.

    • The listed criteria apply to the intended or prescribed use.
    • Requests may not be approved when the criteria are not satisfied.

    Clinical Background

    Leucovorin is folinic acid, a folic acid derivative. Levoleucovorin is the biologically active l-isomer of leucovorin and is dosed at one-half the dose of racemic d,l-leucovorin. These agents may reduce toxicity or counteract impaired elimination of folic acid antagonists such as methotrexate and may enhance fluoropyrimidine effects in cancer treatment.

    Definitions

    Analogue
    DefinitionA drug or substance similar to, but not identical to, another drug or substance.
    SimilarityThe analogue shares characteristics with another drug or substance.
    DistinctionAn analogue is similar to, but remains different from, the other drug or substance.
    Antagonist
    DefinitionAn agent that blocks the binding of an agonist at a receptor site.
    AgonistA substance that binds to a specific receptor and triggers a response in the cell.
    Mechanism

    Initial Therapy Criteria

    Levoleucovorin Initial Therapy

    Levoleucovorin agents may be approved when ANY ONE of the following initial-therapy criteria is met:

    Levoleucovorin initial approval: The individual is under 19 years of age; uses high-dose methotrexate for osteosarcoma or specified oncology indications; requires treatment of impaired methotrexate elimination or folic acid antagonist overdose; receives fluorouracil-based treatment for colorectal adenocarcinoma; or receives another specified NCCN 2A combination-chemotherapy regimen.

    See the coverage criteria for the complete diagnosis and regimen list.

    Vykoura Initial Therapy

    Vykoura may be approved when ANY ONE of the following initial-therapy criteria is met:

    Vykoura initial approval: The individual is under 19 years of age; requires methotrexate rescue or toxicity reduction; has megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible; requires fluorouracil-based or high-dose methotrexate oncology therapy for a listed diagnosis; or requires graft-versus-host disease prophylaxis in combination with methotrexate.
    Policy Summary
    PayerEmpire Bluecross
    PolicyLevoleucovorin and Leucovorin Agents
    Policy CodePolicy CC-0104
    Change TypeModified — annual review
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionUse the applicable medical-necessity criteria to determine coverage when the drug is subject to clinical review or prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and Review RequirementsClinical BackgroundDefinitionsInitial Therapy Criteria
    Bladder cancer.
  1. Bone cancer, including osteosarcoma, dedifferentiated chondrosarcoma, and high-grade undifferentiated pleomorphic sarcoma.
  2. Central nervous system (CNS) cancers, including primary CNS lymphoma, limited brain metastases, extensive brain metastases, or leptomeningeal metastases.
  3. Cervical cancer.
  4. Chronic lymphocytic leukemia/small lymphocytic lymphoma.
  5. Esophageal and esophagogastric junction cancers.
  6. Gastric cancer.
  7. Gestational trophoblastic neoplasia.
  8. Biliary tract cancers, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma.
  9. Neuroendocrine and adrenal tumors, including neuroendocrine tumors of the gastrointestinal tract (well-differentiated grade 1/2), lung, and thymus; well-differentiated grade 3 neuroendocrine tumors; extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine-non-neuroendocrine neoplasm; or pancreatic neuroendocrine tumors.
  10. Occult primary.
  11. Ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, including mucinous carcinoma.
  12. Pancreatic adenocarcinoma.
  13. Small bowel adenocarcinoma.
  14. T-cell lymphomas, including hepatosplenic T-cell lymphoma, peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma, or extranodal NK/T-cell lymphoma.
  15. Thymomas and thymic carcinomas.
  16. Vaginal cancer.
  17. Individual is using in combination with 5-fluorouracil in the treatment of metastatic colorectal cancer.
  18. Individual is using in combination with fluorouracil-based regimens for one of the following cancer diagnoses (NCCN 2A)

    • Pancreatic adenocarcinoma, adenosquamous carcinoma, or squamous carcinoma.
    • Biliary tract cancers, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma.
    • Ovarian cancers, including mucinous neoplasms of the ovary.
    • Neuroendocrine and adrenal tumors, including neuroendocrine tumors of the pancreas (well-differentiated grade 1/2), extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, mixed neuroendocrine-non-neuroendocrine neoplasm, and neuroendocrine tumors of the gastrointestinal tract (well-differentiated grade 1/2), lung, and thymus.
    • Thymomas and thymic carcinomas.
    • Occult primary tumors, including squamous cell carcinoma, adenocarcinoma, or carcinoma not otherwise specified.
    • Cervical cancer, including squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma.
    • Bladder cancer, including non-urothelial and urothelial cancers with subtype histology and pure adenocarcinoma, including urachal cancer.
    • Esophageal and esophagogastric junction cancers.
    • Gastric cancer.
    • Vaginal cancer.
    • Small bowel adenocarcinoma.
    • Anal carcinoma.
    • Appendiceal neoplasms and cancers, including appendiceal adenocarcinoma, undifferentiated carcinoma not otherwise specified, goblet cell adenocarcinoma, low-grade appendiceal mucinous neoplasm, and high-grade appendiceal mucinous neoplasm.
    • Ampullary adenocarcinoma.
  19. Central nervous system (CNS) cancers, including primary CNS lymphoma, brain metastases, and leptomeningeal metastases.
  20. Acute lymphoblastic leukemia (ALL).
  21. Bone cancer, including osteosarcoma, dedifferentiated chondrosarcoma, and high-grade undifferentiated pleomorphic sarcoma.
  22. Acute myeloid leukemia (AML), including blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  23. B-cell lymphomas, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, Burkitt lymphoma, HIV-related B-cell lymphomas, and post-transplant lymphoproliferative disorders.
  24. Denial Risk

    Vykoura Criteria Not Met

    Requests for Vykoura (leucovorin calcium) may not be approved when the applicable clinical criteria are not met.

    • The request must satisfy the applicable listed criteria for the requested indication.
    • Failure to meet the criteria may result in non-approval.
    Denial Risk

    Unlisted Vykoura Indications Not Approved

    Requests for Vykoura (leucovorin injection) may not be approved for indications other than those addressed by the policy criteria, including requests that do not meet the listed criteria.

    • Other indications are not approved under the listed criteria.
    • Review the applicable criteria before submitting a Vykoura request.
    The antagonist prevents the agonist from binding at the receptor site.
    Isomer
    DefinitionA drug or substance that shares the same chemical formula as another but has a different molecular arrangement.
    Stereoisomersl-LV and d-LV are stereoisomers that are non-superimposable mirror images of each other.
    Therapeutic effectsl-LV and d-LV have been shown to have equivalent therapeutic effects.
    Metastasis
    DefinitionThe spread of cancer from one part of the body to another.
    Metastatic tumorA metastatic tumor contains cells that are like those in the original, or primary, tumor.
    OriginThe cancer cells have spread from the primary tumor to another part of the body.
    Neuroendocrine tumor
    DefinitionA tumor that forms from cells that release hormones into the blood in response to a signal from the nervous system.
    Hormone productionNeuroendocrine tumors may make higher-than-normal amounts of hormones, which can cause many different symptoms.
    Tumor classificationNeuroendocrine tumors may be benign, meaning not cancerous, or malignant, meaning cancerous.

    See the coverage criteria for the complete diagnosis and regimen list.